In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eating Our Seed Corn

Executive Summary

The drug industry's preoccupation with late-stage products means they're largely ignoring early-stage companies. But unlike earlier years, these biotechs have no financing alternative: the stock market now marches in lockstep with Big Pharma trends. But as the extraordinary valuations of the large biotechs shows, the early-stage companies of today can be the late-stage companies of tomorrow--and the source of Big Pharma's late-stage product opportunities. If drug firms don't act now to encourage early-stage investment--either through lobbying for governmental investment incentives or through their own venture investing--they may, in focusing so exclusively on late-stage deals, be eating their own seed corn.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts